Photogen restructures to focus on core products:
This article was originally published in Clinica
New Hope, Pennsylvania-based Photogen Technologies will use the $16.25m raised from financing agreements to implement its restructuring plan, allowing it to concentrate resources on its cardiovascular imaging and lymphography products, PH-50 and N-1177, respectively. The company is splitting off its photodynamic therapy and laser device business to five founding shareholders, in exchange for all their common stock, some 52.9% of the company's shares.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.